Sun Pharmaceutical Industries Limited appears to be a financially stable company with a strong gross margin of 79.56% and EBITDA margin of 28.69%. The company's ROE of 15.71% indicates efficient use of shareholder capital. However, the company's revenue and earnings growth rates are sluggish, with earnings growth being negative. The company's valuation seems stretched with a trailing P/E of 36.48 and forward P/E of 50.85. Additionally, the debt-to-equity ratio of 3.26 is a concern, indicating a high level of leverage.